GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIVATION REDUCES COMPENSATORY HYPERTROPHY AND LEFT VENTRICULAR REMODELING IN A PORCINE MODEL OF ISCHEMIA AND REPERFUSION  by Vahl, Torsten et al.
E547
JACC March 27, 2012
Volume 59, Issue 13
Acute Coronary Syndromes 
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIVATION REDUCES COMPENSATORY HYPERTROPHY AND 
LEFT VENTRICULAR REMODELING IN A PORCINE MODEL OF ISCHEMIA AND REPERFUSION
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Sunday, March 25, 2012, 11:00 a.m.-Noon
Session Title: Acute Coronary Syndromes: Clinical XII
Abstract Category: 6. Acute Coronary Syndromes: Basic
Presentation Number: 1172-439
Authors: Torsten Vahl, Carlos Santos-Gallego, Teresa Arias, Maria Lopez-Benito, Javier Sanz, Martin Goldman, Roger Hajjar, Valentin Fuster, Juan 
Badimon, Mount Sinai School of Medicine, New York, NY, USA
Background: Glucagon-like Peptide-1 (GLP-1) is an intestinal hormone important for glucose metabolism. Recent attention has focused on its 
anti-apoptotic and cytoprotective actions. Exenatide is a GLP-1 mimetic used to treat Type 2 diabetes. Our group has demonstrated that Exenatide-
mediated GLP-1receptor (GLP-1r) activation reduces acute myocardial injury during ischemia and reperfusion. We sought to determine if GLP-1r 
activation plays a protective role in left ventricular remodeling following myocardial infarction (MI).
Methods: Acute MI was induced in Yorkshire pigs by balloon occlusion of the proximal LAD for 60 minutes, followed by reperfusion. Animals 
randomly received either Exenatide (10 μg i.v.; n=6) 10 minutes prior to reperfusion and then twice daily for the next 3 days, or saline for controls 
(n=6). Cardiac remodeling was assessed by cardiac MRI, histology and Western blot at one month post MI.
Results: One month after MI induction, Exenatide-treated animals had 18% lower left ventricular (LV) mass than controls, measured by cardiac 
MRI (LV mass 58.7 ± 1.9 g vs. 71.4 ± 2.0 g, p < 0.05). Across groups we found an inverse correlation between LV function and LV mass (r = 0.91, 
p < 0.05). Histomorphometry revealed that cardiomyocyte perimeter (149.9 ± 6.6 μm vs. 177.5 ± 4.0 μm) and cross-sectional area (1493.1 ± 
127.3 μm2 vs. 2085.2 ± 88.3 μm2) were significantly lower with Exenatide, demonstrating less hypertrophy. Exenatide treatment lead to a trend in 
reduction of proteins linked to myocardial hypertrophy signaling pathways. Specifically, the pAKT/AKT ratio and the pERK/ERK ratio were reduced by 
65% and 34%, respectively. Further, myocardial fibrosis in the border zone was reduced by 65% in Exenatide-treated animals (p<0.05).
Conclusions: Our results indicate that GLP-1r activation by Exenatide reduced compensatory hypertrophy and LV remodeling one month following 
MI. These data support a cardioprotective role for GLP-1 signaling that extends beyond the acute phase of myocardial ischemia. Our findings suggest 
that activating the GLP-1 system in patients with MI has great therapeutic potential to reduce the development of ischemic cardiomyopathy.
